Skip to main content
76 search results for:

Pemetrexed 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 25-03-2020 | Non-small-cell lung cancer | News | Article

    Carboplatin–pemetrexed should be ‘a standard option’ for older NSCLC patients

    Carboplatin–pemetrexed plus pemetrexed maintenance is noninferior to docetaxel for the first-line treatment of advanced non-small-cell lung cancer in patients aged 75 years or older, suggests a phase 3 Japanese study.

  2. 20-06-2019 | Non-small-cell lung cancer | News | Article

    Maintenance bevacizumab–pemetrexed improves PFS of nonsquamous NSCLC patients

    Two studies presented at the 2019 ASCO Annual Meeting show a significant progression-free survival, but not overall survival, benefit with the addition of pemetrexed to bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer.

  3. 27-03-2018 | EMA | News | Article
    approvalsWatch

    EMA updates for biosimilar trastuzumab, generic pemetrexed

    This announcement follows the US FDA’s approval of the biosimilar trastuzumab-dkst for the treatment of breast and gastric cancer with HER2 overexpression. --- The EMA’s Committee for Medicinal Products for Human Use has also given a positive opinion for marketing authorization of pemetrexed Krka , a generic formulation of the antifolate agent pemetrexed.

  4. 10-10-2016 | Pembrolizumab | Article

    Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Langer CJ et al. Lancet Oncol 2016; 17(11): 1497–1508. doi: 10.1016/S1470-2045(16)30498-3

  5. 26-01-2023 | Non-small-cell lung cancer | News | Article

    Adding camrelizumab to chemo prolongs OS of patients with advanced nonsquamous NSCLC

    In the phase 3 study, 412 Chinese patients with stage IIIB–IV nonsquamous disease were randomly assigned to receive four to six cycles of camrelizumab 200 mg alongside carboplatin plus pemetrexed every 3 weeks or chemotherapy alone, followed by maintenance pemetrexed with or without camrelizumab.

  6. 14-10-2022 | Non-small-cell lung cancer | News | Article

    CHOICE-01 shows survival benefit of adding toripalimab to chemo in advanced NSCLC

    This was followed by maintenance treatment with toripalimab or placebo as per the random assignment, with nonsquamous NSCLC patients continuing with pemetrexed.

  7. 05-09-2022 | Lung cancer | News | Article

    First-line cemiplimab prolongs advanced NSCLC survival irrespective of PD-L1 expression

    In the current study, 466 patients with stage III (14.8%) or IV (85.2%) NSCLC without EGFR , ALK , or ROS1 genomic tumor aberrations were randomly assigned to receive cemiplimab 350 mg (n=312) or placebo (n=154) every 3 weeks for up to 108 weeks each in combination with four cycles of an investigator’s choice of platinum-doublet chemotherapy, followed by pemetrexed maintenance where indicated.

  8. 04-08-2022 | Non-small-cell lung cancer | News | Article

    Combined sintilimab, bevacizumab biosimilar plus chemo supported for EGFR-mutated NSCLC

    Moving onto the safety, Shun Lu (Shanghai Jiao Tong University, China) and team say that “sintilimab plus IBI305 plus cisplatin and pemetrexed was generally well tolerated with no new safety signals.”

  9. 08-06-2022 | ASCO 2022 | Conference coverage | Article

    Lung-MAP: Post-immunotherapy ramucirumab plus pembrolizumab improves NSCLC survival

    This was significantly longer than the median OS of 11.6 months among the 67 given investigator's choice of docetaxel plus ramucirumab (n=45), gemcitabine (n=12), docetaxel (n=3), pemetrexed (n=1), or no treatment (n=6).

  10. 04-06-2022 | ASCO 2022 | Conference coverage | Article

    Amivantamab updates confirm NSCLC efficacy for certain patients

    She said that the phase 3 MARIPOSA and MARIPOSA-2 trials are now investigating amivantamab plus lazertinib as a first-line regimen. and in combination with carboplatin plus pemetrexed after osimertinib, respectively.

  11. 15-02-2022 | Mesothelioma | News | Article

    MiST2 points to potential of abemaciclib in malignant mesothelioma

    All had disease of pleural origin and had received at least one prior line of systemic therapy, including standard first-line pemetrexed plus either cisplatin or carboplatin.

  12. 20-01-2022 | Non-small-cell lung cancer | News | Article

    Sugemalimab shows promise for locally advanced, metastatic NSCLC

    Participants were randomly assigned to receive either sugemalimab 1200 mg (n=320) or placebo (n=159) every 3 weeks alongside up to four cycles of chemotherapy (carboplatin plus pemetrexed for nonsquamous and carboplatin plus paclitaxel for squamous disease), followed by maintenance with sugemalimab or placebo for up to 35 cycles, with pemetrexed given to patients with nonsquamous disease.

  13. 14-09-2021 | WCLC 2021 | Conference coverage | Article

    No new safety signals for neoadjuvant, maintenance atezolizumab in mesothelioma

    Neoadjuvant atezolizumab meets researcher-defined safety criteria for use in combination with cisplatin plus pemetrexed and then as postsurgical maintenance therapy for people with resectable malignant pleural mesothelioma.

  14. 13-09-2021 | WCLC 2021 | Conference coverage | Article

    Atezolizumab plus chemotherapy feasible for NSCLC with brain metastases

    Treatment with carboplatin and pemetrexed plus atezolizumab shows promise for people with nonsquamous non-small-cell lung cancer and asymptomatic, untreated brain metastases, phase 2 study findings indicate.

  15. 15-09-2021 | Non-small-cell lung cancer | News | Article

    No overall survival benefit with first-line bevacizumab–erlotinib in EGFR-mutant NSCLC

    Specifically, 75.9% of patients in the combination arm received a second-line treatment as did 83.0% of those in the erlotinib monotherapy arm, most commonly osimertinib (27.7 and 25.9%, respectively), platinum-based chemotherapy plus pemetrexed (29.5 and 16.1%), and platinum-based chemotherapy plus pemetrexed and bevacizumab (4.5 and 28.6%).

  16. 17-09-2021 | ESMO 2021 | Conference coverage | Article

    Updated CheckMate 743 data support dual checkpoint blockade in mesothelioma

    She reported on an analysis conducted at a minimum follow-up of 35.5 months, which showed that the risk for death was a significant 27% lower for the 303 patients who were randomly assigned to receive nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks for up to 2 years than for the 302 patients who instead received six cycles of cisplatin or carboplatin plus pemetrexed every 3 weeks.

  17. 08-02-2021 | Non-small-cell lung cancer | News | Article
    WCLC 2020

    ITACA pharmacogenomic adjuvant chemotherapy approach does not boost resected NSCLC outcomes

    Patients were therefore randomly assigned to receive the regimens as below: High ERCC1 , high TS – paclitaxel alone (n=137) or control (n=127); High ERCC1 , low TS – pemetrexed alone (n=35) or control (n=41); Low ERCC1 , high TS – cisplatin plus gemcitabine (n=85) or control (n=98); Low ERCC1 , low TS – cisplatin plus pemetrexed (n=87) or control (n=80).

  18. 04-05-2021 | Non-small-cell lung cancer | News | Article
    News in brief

    KEYNOTE-189 final analysis confirms pembrolizumab nonsquamous NSCLC benefits

    The addition of pembrolizumab to pemetrexed–paclitaxel chemotherapy provides durable survival advantages for treatment-naïve patients with metastatic, nonsquamous non-small-cell lung cancer, the final protocol-specified analysis of KEYNOTE-189 has confirmed.

  19. 01-06-2021 | Non-small-cell lung cancer | News | Article

    Tislelizumab benefit demonstrated in advanced nonsquamous NSCLC

    The study investigators enrolled 334 treatment-naïve patients with stage IIIB–IV nonsquamous disease lacking sensitizing EGFR or ALK alterations, and randomly assigned them to receive four to six cycles of carboplatin AUC 5 or cisplatin 75 mg/m 2 plus pemetrexed 500 mg/m 2 every 3 weeks either with or without tislelizumab 200 mg, followed by maintenance with tislelizumab plus pemetrexed and pemetrexed alone, respectively.

  20. 13-05-2021 | Non-small-cell lung cancer | News | Article

    Real-world pneumonitis rates with pembrolizumab–chemotherapy exceed clinical trial data

    The study included 299 patients with treatment-naïve, stage III–IV or recurrent, nonsquamous NSCLC who received the combination of pembrolizumab, pemetrexed, and platinum-based chemotherapy at one of 36 Japanese hospitals between December 2018 and June 2019.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.